Cargando…
Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization
PURPOSE: The purpose of this study is to evaluate the use of density measurements in the diagnosis of an underlying residual tumor beyond iodine depositions after Lipiodol-based conventional transarterial chemoembolization (cTACE). METHOD AND MATERIALS: Thirty follow-up CT scans of 20 patients 6–12...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988944/ https://www.ncbi.nlm.nih.gov/pubmed/31995589 http://dx.doi.org/10.1371/journal.pone.0227972 |
_version_ | 1783492336277258240 |
---|---|
author | Haubold, Johannes Ludwig, Johannes M. Li, Yan Buechter, Matthias Wetter, Axel Umutlu, Lale Theysohn, Jens M. |
author_facet | Haubold, Johannes Ludwig, Johannes M. Li, Yan Buechter, Matthias Wetter, Axel Umutlu, Lale Theysohn, Jens M. |
author_sort | Haubold, Johannes |
collection | PubMed |
description | PURPOSE: The purpose of this study is to evaluate the use of density measurements in the diagnosis of an underlying residual tumor beyond iodine depositions after Lipiodol-based conventional transarterial chemoembolization (cTACE). METHOD AND MATERIALS: Thirty follow-up CT scans of 20 patients 6–12 weeks after Lipiodol-based cTACE, receiving a digital subtraction angiography at the same time, were analyzed. Reference for the detection of a residual tumor was the angiography, and a visible contrast enhancement was categorized as a residual tumor (n = 16 with residual tumor; n = 14 without residual tumor). The density of the iodine depositions was measured in all containing slices in non-contrast-, arterial- and portal venous-phase CT scans, with a slice thickness of 5.00 mm. The mean density of the iodine deposition during the portal venous phase was subtracted from the mean density of the arterial phase to calculate the density changes (a positive enhancement score represents washout in the portal venous phase). In addition, a quotient relating to the non-contrast measurement was evaluated. RESULTS: Patients with a residual tumor displayed significantly higher enhancement scores in favor of density reduction between the arterial and portal venous phases, compared to patients without a residual tumor (1.41 ± 3.59, n = 14 vs. -13.97 ± 2.88, n = 16; p-value < 0.01). Furthermore, 87.75% of patients with an enhancement score higher than -1.00 (n = 9) had a residual tumor, whereas 100.00% of patients with an enhancement score lower than -20.00 (n = 6) were shown to be tumor-free. The enhancement score quotient resulted in similar findings. CONCLUSION: After cTACE in patients with hepatocellular carcinoma (HCC), the presence of a viable tumor correlated with enhancement scores based on the density measurements of iodine depositions in different phases of the CT scan. Low enhancement scores were associated with completely treated tumors and can aid the decision process to avoid possibly unnecessary angiographies. |
format | Online Article Text |
id | pubmed-6988944 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-69889442020-02-04 Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization Haubold, Johannes Ludwig, Johannes M. Li, Yan Buechter, Matthias Wetter, Axel Umutlu, Lale Theysohn, Jens M. PLoS One Research Article PURPOSE: The purpose of this study is to evaluate the use of density measurements in the diagnosis of an underlying residual tumor beyond iodine depositions after Lipiodol-based conventional transarterial chemoembolization (cTACE). METHOD AND MATERIALS: Thirty follow-up CT scans of 20 patients 6–12 weeks after Lipiodol-based cTACE, receiving a digital subtraction angiography at the same time, were analyzed. Reference for the detection of a residual tumor was the angiography, and a visible contrast enhancement was categorized as a residual tumor (n = 16 with residual tumor; n = 14 without residual tumor). The density of the iodine depositions was measured in all containing slices in non-contrast-, arterial- and portal venous-phase CT scans, with a slice thickness of 5.00 mm. The mean density of the iodine deposition during the portal venous phase was subtracted from the mean density of the arterial phase to calculate the density changes (a positive enhancement score represents washout in the portal venous phase). In addition, a quotient relating to the non-contrast measurement was evaluated. RESULTS: Patients with a residual tumor displayed significantly higher enhancement scores in favor of density reduction between the arterial and portal venous phases, compared to patients without a residual tumor (1.41 ± 3.59, n = 14 vs. -13.97 ± 2.88, n = 16; p-value < 0.01). Furthermore, 87.75% of patients with an enhancement score higher than -1.00 (n = 9) had a residual tumor, whereas 100.00% of patients with an enhancement score lower than -20.00 (n = 6) were shown to be tumor-free. The enhancement score quotient resulted in similar findings. CONCLUSION: After cTACE in patients with hepatocellular carcinoma (HCC), the presence of a viable tumor correlated with enhancement scores based on the density measurements of iodine depositions in different phases of the CT scan. Low enhancement scores were associated with completely treated tumors and can aid the decision process to avoid possibly unnecessary angiographies. Public Library of Science 2020-01-29 /pmc/articles/PMC6988944/ /pubmed/31995589 http://dx.doi.org/10.1371/journal.pone.0227972 Text en © 2020 Haubold et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Haubold, Johannes Ludwig, Johannes M. Li, Yan Buechter, Matthias Wetter, Axel Umutlu, Lale Theysohn, Jens M. Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization |
title | Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization |
title_full | Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization |
title_fullStr | Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization |
title_full_unstemmed | Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization |
title_short | Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization |
title_sort | measuring the density of iodine depositions: detecting an invisible residual tumor after conventional transarterial chemoembolization |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988944/ https://www.ncbi.nlm.nih.gov/pubmed/31995589 http://dx.doi.org/10.1371/journal.pone.0227972 |
work_keys_str_mv | AT hauboldjohannes measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization AT ludwigjohannesm measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization AT liyan measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization AT buechtermatthias measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization AT wetteraxel measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization AT umutlulale measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization AT theysohnjensm measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization |